Ján Murín, Miroslav Pernický, Marta Filková, Soňa Kiňová
The paper deals with treatment of chronic heart failure and offers also outlook for near future. There are two types of heart failure, ‘systolic type’ (with ejection fraction less than 40 %) and so-called ‘diastolic type’ (heart failure with preserved ejection fraction, i.e. over 40 %), at which the author analyses differences in pathophysiology of the disease. Nowadays “evidence based treatment” is related only to systolic type of the disease (RAAS blockers, sympaticus blockers, ivabradine, diuretics, but also digoxin, warfarin, or other treatment). In ‘the diastolic type’ of heart failure we treat mainly comorbidities. In near future we expect a bigger practical benefit of biomarkers (natriuretic peptides, troponins) at the treatment of chronic heart failure, but also bigger entrance of education about heart failure (by nurses) and participation of so-called heart failure units in clinical practice. But demanding diseases, comorbidities and high age of patients deserve such solution.